+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


Recent Advances across Cancer Biomarkers - Genetic TOE

  • ID: 4012825
  • Report
  • August 2016
  • Region: Global
  • 15 pages
  • Frost & Sullivan
1 of 2

Enquire about COVID-19 updates for this product.

Enquire Now
This edition of the Genetic Technology TOE depicts the current landscape and the new life sciences trends across cancer biomarkers. The corresponding patent scenario is depicted along with the industry interactions.

The Genetic Technology TechVision Opportunity Engine (TOE) presents the latest R&D developments and advances with an emphasis on opportunities to profit in the explosive field of genetic technology through technology transfer, joint ventures, and acquisitions. The complete gamut of genetic technology applications is covered including the latest developments in omics technologies; genetic, cellular, and alternative therapies; sequencing technologies; and genetically altered animals and plants.

The Health & Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare.
Note: Product cover images may vary from those shown
2 of 2
Trend Overview
  • Trends in Cancer Biomarkers
Applications Summary
  • Analysis of Disease-Specific Applications for Cancer Biomarkers
  • Overview of Cancer Biomarker Utilities
Technology Profiles
  • New Biomarker Assay for PD-L1
  • Gene Signature Assay for Breast Cancer Recurrence
  • Novel Blood Test for Colorectal Cancer Screening
Strategic Perspectives
  • Analyst Insights on Cancer Biomarkers
  • Patent Scenario
  • Patent Scenario
  • Industry Interactions
Note: Product cover images may vary from those shown
3 of 2